October 25, 2026 01:51 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Jamia shifts classes online after clash over demand for student union polls; Congress MPs face allegations | Deadly mid-air collision: Four pilots killed as two military aircraft crash in Philippines | ‘Jihad’ calls, Modi assassination remarks: Mumbai Rapido driver arrested over alleged Jaish links | Vegetarian-only kitchen at Keralam Lok Bhavan? Governor's reported order triggers political backlash | ‘Another little Epic Fury’: Trump’s chilling warning to Iran as fresh US strikes loom | Bomb threat email names Amitabh Bachchan’s Jalsa bungalow, Diljit Dosanjh’s concert venue: Reports | ‘Face-offs still continue’: ITBP chief reveals fresh India-China border tensions in Arunachal | Eiffel Tower women staff row: BAPS monk blames ‘miscommunication’, denies delegation's role | ‘Pen, not stones and guns’: RSS-linked group opens its first office in Kashmir Valley under Muslim leader | First human case of Shamonda virus reported in France; WHO confirms death of immunocompromised patient
Pfizer-BioNTech
WIKIMEDIA COMMONS

Sri Lanka approves Pfizer vaccine, orders five million doses

| @indiablooms | May 09, 2021, at 04:18 am

Sri Lanka has approved the Pfizer-BioNTech COVID-19 vaccine for emergency use and prepared a purchase order for five million doses, an official said.

State Minister Sudarshini Fernandopulle’s media secretary confirmed to EconomyNext that the National Medicines Regulatory Authority (NMRA) granted its approval for the jab on Friday.

The Pfizer-BioNTech vaccine is one of the two pioneering jabs the World Health Organisation (WHO) approved  for emergency use, the other being the Oxford-AstaZeneca vaccine that Sri Lanka used to inoculate some 900,000 people including frontline workers.

The WHO approved the Pfizer jab for emergency use on December 31 last year.

The vaccine is produced by the US-based Pfizer pharmaceutical company and has shown the efficacy of 95 per cent against symptomatic SARS-CoV-2 virus.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.